Professor, Department of Surgical Oncology
Surgery and chemotherapy for all gynecologic cancers; minimally invasive surgery for gynecologic cancers, precancerous conditions and benign gynecologic conditions
| Gynecologic Oncology |
I joined Fox Chase Cancer Center in 2014 as chief of the Division of Gynecologic Oncology. I spent the early part of my medical career at Memorial Sloan-Kettering Cancer Center in New York and the Hospital of the University of Pennsylvania, where I was chief of gynecologic oncology. As a gynecologic oncologist, I have extensive training and experience in surgery (including minimally invasive) for gynecologic cancers and for complex benign gynecologic conditions. I also provide the full range of chemotherapy options for gynecologic cancers, giving my patients the continuity of care that comes with multimodal cancer care.
I am delighted to be practicing at Fox Chase, where I offer patients state-of-the-art care, including innovative clinical trials, in a caring, compassionate environment, with all the support services that come from an NCI-designated Comprehensive Cancer Center.
For decades, my healthcare routine was the same: When I scheduled my annual mammogram to screen for breast cancer, I also booked an appointment for a preventative transvaginal ultrasound. That’s because my sister survived a bout with uterine cancer 40 years ago, and our family history could put me at risk of developing the same cancer.
Resilience, Positive Coping, and Quality of Life Among Women Newly Diagnosed With Gynecological Cancers. Manne SL, Myers-Virtue S, Kashy D, Ozga M, Kissane D, Heckman C, Rubin SC, Rosenblum N. Cancer Nurs. 2015 Sep-Oct;38(5):375-82. doi: 10.1097/NCC.0000000000000215.
Correlation of pelvic magnetic resonance imaging diagnosis with pathology for indeterminate adnexal masses. Haggerty AF, Hagemann AR, Chu C, Siegelman ES, Rubin SC. Int J Gynecol Cancer. 2014 Sep;24(7):1215-21. doi: 10.1097/IGC.0000000000000203. PMID: 25153677
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX. J Clin Oncol. 2014 Apr 20;32(12):1210-7. doi: 10.1200/JCO.2013.53.6524. Epub 2014 Mar 17. PMID: 24637999
Paget Cells in Endometrial and Endocervical Curettings in a Patient With Recurrent Vulvar Paget's Disease. Clayton EF, Rubin SC, Dumoff KL. Int J Surg Pathol. 2014 Jun;22(4):374-7. doi: 10.1177/1066896913498819. Epub 2013 Aug 5. PMID: 23918905
Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, Levine BL, Coukos G, Rubin SC, Morgan MA, Vonderheide RH, June CH. Cancer Immunol Immunother. 2012 May;61(5):629-41. doi: 10.1007/s00262-011-1081-8. Epub 2011 Oct 22. PMID: 22021066
A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Adams SF, Marsh EB, Elmasri W, Halberstadt S, Vandecker S, Sammel MD, Bradbury AR, Daly M, Karlan B, Rubin SC. Gynecol Oncol. 2011 Dec;123(3):486-91. doi: 10.1016/j.ygyno.2011.08.032. Epub 2011 Sep 25. PMID: 21945552
Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma. Hagemann AR, Hagemann IS, Cadungog M, Hwang WT, Patel P, Lal P, Hammond R, Gimotty PA, Chu CS, Rubin SC, Birrer MJ, Powell DJ Jr, Feldman MD, Coukos G. Cancer Biol Ther. 2011 Aug 15;12(4):367-77. Epub 2011 Aug 15. PMID: 21785280
Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment. Hagemann AR, Cadungog M, Hagemann IS, Hammond R, Adams SF, Chu CS, Rubin SC, Zhang L, Addya K, Birrer MJ, Gimotty PA, Coukos G. Cancer Biol Ther. 2011 Aug 15;12(4):357-66. Epub 2011 Aug 15. PMID: 21785264
Clinical predictors of bevacizumab-associated gastrointestinal perforation. Tanyi JL, McCann G, Hagemann AR, Coukos G, Rubin SC, Liao JB, Chu CS. Gynecol Oncol. 2011 Mar;120(3):464-9. doi: 10.1016/j.ygyno.2010.11.009. Epub 2010 Dec 17. PMID: 21168199
Vaginal intraepithelial neoplasia (VAIN) after radiation therapy for gynecologic malignancies: a clinically recalcitrant entity. Liao JB, Jean S, Wilkinson-Ryan I, Ford AE, Tanyi JL, Hagemann AR, Lin LL, McGrath CM, Rubin SC. Gynecol Oncol. 2011 Jan;120(1):108-12. doi: 10.1016/j.ygyno.2010.09.005. PMID: 20937524
Patient comments